Evidence-based GCC nursing reference covering KDIGO staging, assessment, management, RRT, and prevention — with interactive clinical tools.
AKI is defined by any one of the following criteria (KDIGO 2012):
Serum creatinine increase ≥26.5 μmol/L within 48 hours
Serum creatinine rise to ≥1.5× known or presumed baseline within the prior 7 days
Urine output <0.5 mL/kg/h for ≥6 consecutive hours
Creatinine: ×1.5–1.9 baseline or rise ≥26.5 μmol/L
Urine Output: <0.5 mL/kg/h for 6–12 h
Action: Identify cause, optimise fluids, stop nephrotoxins
Creatinine: ×2.0–2.9 baseline
Urine Output: <0.5 mL/kg/h for ≥12 h
Action: Nephrology review, intensive monitoring
Creatinine: ×3.0+ baseline, ≥353.6 μmol/L, or RRT initiation
Urine Output: <0.3 mL/kg/h for ≥24 h or anuria ≥12 h
Action: ICU/HDU, consider RRT
Apply THINK prompt to all high-risk admissions to screen for reversible AKI causes
The GCC region carries elevated AKI risk: extreme heat climate causing dehydration, high prevalence of NSAID use for musculoskeletal pain, high rates of iodinated contrast procedures, and a high background burden of diabetes mellitus and hypertension — the two leading causes of CKD and AKI susceptibility.
| Test | Pre-Renal Result | Intrinsic (ATN) Result | Clinical Significance |
|---|---|---|---|
| Urine dipstick blood + protein | Negative | Positive | Intrinsic/GN/infection |
| Urine osmolality : plasma ratio | >1.5 | <1.1 | >1.5 = concentrating → pre-renal |
| Urine sodium (mmol/L) | <20 | >40 | Tubular reabsorption intact in pre-renal |
| FENa (%) | <1% | >2% | FENa = (urine Na × plasma Cr) / (plasma Na × urine Cr) × 100 |
| Urine: granular casts | Absent | Present | ATN — hallmark finding |
| Urine: RBC casts | Absent | Present | Glomerulonephritis |
| Urine: WBC casts | Absent | Present | Pyelonephritis / interstitial nephritis |
Note: FENa unreliable if patient on diuretics — use FEUrea instead (<35% pre-renal)
Hydronephrosis → post-renal obstruction (dilated pelvicalyceal system)
Small, bright (echogenic) kidneys → CKD (chronic disease, not AKI)
Normal size (10–12 cm) supports acute process
Duplex Doppler for renal vascular causes
CT KUB — if urinary stone suspected (no contrast needed)
Kidney biopsy — native kidney biopsy for glomerular disease, unexplained intrinsic AKI, interstitial nephritis confirmation
Requires USS guidance, INR <1.5, platelets >80
Hyperkalaemia (K+ >6.0 mmol/L) and severe metabolic acidosis (pH <7.2) require immediate management before addressing the underlying AKI cause.
Resume medications after AKI resolution — nephrology guidance required
Urethral catheterisation — immediate relief. Clamp catheter for 30 minutes every 500 mL if large bladder to prevent haematuria ex-vacuo.
Post-obstructive diuresis expected — replace urine output 50–75% with IV fluids, monitor electrolytes closely.
Percutaneous nephrostomy (urology/interventional radiology) — urgent referral for bilateral ureteric obstruction or obstruction in solitary kidney.
Ureteric stenting (JJ stent) as alternative or subsequent procedure.
| Intrinsic Cause | Specific Treatment | Urgency |
|---|---|---|
| Sepsis-AKI (most common) | Antibiotics (1h target), source control, IV fluids, vasopressors for MAP ≥65 | Emergency |
| Drug-induced interstitial nephritis | STOP causative drug, corticosteroids (prednisolone 1 mg/kg/d) if no improvement | Urgent |
| Rapidly progressive GN (RPGN) | Pulsed IV methylprednisolone ± cyclophosphamide, plasma exchange if anti-GBM | Emergency |
| TMA / HUS / TTP | Plasma exchange (TTP), eculizumab (aHUS), treat underlying cause | Emergency |
| Rhabdomyolysis-AKI | Aggressive IV fluids (target UO 200–300 mL/h), consider urine alkalinisation if myoglobinuria | Urgent |
| Contrast-induced AKI | Pre/post hydration with 0.9% NaCl, IOCM, withhold metformin 48h | Prevention |
Most life-threatening complication of AKI — act immediately. Use interactive tool in Tab 6 for individualised guidance.
3–4 hour sessions, typically 3×/week. High-efficiency solute clearance. Risk of haemodynamic instability — rapid fluid and solute shifts.
Continuous infusion 24 h/day in ICU. Haemodynamically gentle — slow fluid/solute removal. Preferred for unstable patients and cerebral oedema.
Hybrid: 6–12 hour sessions (slow low-efficiency daily dialysis). Combines benefits of IHD efficiency and CRRT haemodynamic tolerance.
| Modality | Mechanism | Clearance Type | Replacement Fluid |
|---|---|---|---|
| CVVH Continuous Veno-Venous Haemofiltration | Convection — hydrostatic pressure drives plasma water + dissolved solutes across membrane | Convective (larger molecules) | Yes — pre/post dilution |
| CVVHD Continuous Veno-Venous Haemodialysis | Diffusion — concentration gradient across membrane with dialysate counter-current flow | Diffusive (small molecules) | No |
| CVVHDF Haemodiafiltration | Combined convection + diffusion | Both small & medium molecules | Yes |
Target effluent dose: 20–25 mL/kg/h (RENAL and RAVE trials — higher doses ≥35 mL/kg/h showed no additional benefit). Prescribe higher to account for circuit downtime.
Apply to all patients with AKI (Stage 1+) and high-risk patients on admission
GCC hospitals increasingly deploying electronic AKI alerting systems (based on UK NADIA model) — automated lab-triggered alerts when creatinine meets AKI criteria, prompting care bundle activation.
Rise in serum creatinine ≥26.5 μmol/L OR ≥25% above baseline within 48 hours of IV iodinated contrast administration.
Construction workers and labourers working outdoors in extreme GCC summer heat (temperatures exceeding 45°C) are at high risk of exertional heat stroke and rhabdomyolysis-AKI — a unique regional occupational health concern.
Click "Show Answer" to reveal the correct answer and explanation
| Parameter | Value | Clinical Relevance |
|---|---|---|
| AKI creatinine rise (48h) | ≥26.5 μmol/L | KDIGO definition criterion 1 |
| AKI creatinine baseline (7d) | ≥1.5× | KDIGO definition criterion 2 |
| AKI urine output threshold | <0.5 mL/kg/h × 6h | KDIGO definition criterion 3 |
| Stage 3 creatinine absolute | ≥353.6 μmol/L | Or ×3.0 baseline or RRT |
| Pre-renal urine sodium | <20 mmol/L | Intact tubular reabsorption |
| ATN urine sodium | >40 mmol/L | Tubular dysfunction |
| Pre-renal FENa | <1% | Avid sodium retention |
| ATN FENa | >2% | Tubular cell damage |
| CRRT effluent dose | 20–25 mL/kg/h | RENAL/RAVE trial recommendation |
| RCA systemic iCa target | 1.1–1.3 mmol/L | Monitor 4–6 hourly |
| RCA circuit iCa target | 0.25–0.40 mmol/L | Post-filter sample |
| Dialysis K+ threshold | >6.5 mmol/L refractory | AEIOU indication |
| Dialysis pH threshold | <7.1 refractory | AEIOU indication |
| AKI → CKD risk | 25% | All AKI need 3-month nephrology follow-up |